Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:antipsychotic_medication
|
| gptkbp:alsoKnownAs |
loxapine succinate
|
| gptkbp:approvedBy |
1975
|
| gptkbp:ATCCode |
N05AA09
|
| gptkbp:developedBy |
Aventis Pharmaceuticals
|
| gptkbp:drugClass |
typical antipsychotic
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
gptkb:dopamine_receptor_antagonist
|
| gptkbp:routeOfAdministration |
oral
intramuscular injection |
| gptkbp:sideEffect |
weight gain
sedation dry mouth extrapyramidal symptoms |
| gptkbp:usedFor |
treatment of schizophrenia
|
| gptkbp:bfsParent |
gptkb:USS_Fitch_(DD-462)
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
DMS-25
|